Advertisement

Annals of Hematology

, Volume 98, Issue 8, pp 1991–1992 | Cite as

Successful management of transcatheter aortic valve implantation by platelet transfusions in a nonagenarian patient with severe autoimmune factor V deficiency

  • Christine Mouton
  • Lionel Leroux
  • Guillaume Bonnet
  • Benjamin Seguy
  • Aurélie Lafargue
  • Gildas Baulier
  • Sabine Castet
  • Mathieu FioreEmail author
Letter to the Editor
  • 37 Downloads

Dear Editor,

The most common acquired inhibitors to coagulation factors, after factor VIII or von Willebrand factor, are directed against factor V (FV) [1, 2, 3]. Bleeding risk associated with FV inhibitors is highly variable with poor correlation to coagulation studies rendering this disease challenging to manage [4]. Here, we report the successful management of a transcatheter aortic valve implantation (TAVI), using platelet concentrates, in a nonagenarian patient with severe FV inhibitors.

The patient was a 93-year-old woman who was hospitalized in an emergency situation due to acute congestive heart failure. The cause of heart disease included coronary artery diseases, atrial fibrillation, and severe aortic stenosis. During her hospitalization, she developed urinary tract infection treated by ceftriaxone.

Few days later, cardiologists decided to undergo coronary angiography. However, systematic preoperative monitoring revealed very prolonged prothrombin time (PT: 225 s) and...

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethic statement

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008.

Informed consent

Informed consent was obtained from the patient for being included in the study.

References

  1. 1.
    Franchini M, Lippi G (2011) Acquired factor V inhibitors: a systematic review. J Thromb Thrombolysis 31:449–457CrossRefGoogle Scholar
  2. 2.
    De Maertelaere E, Castoldi E, Van Haute I, Deeren D, Devreese KM (2018) The interaction of factor V and tissue factor pathway inhibitor in a myeloma patient with acquired factor V deficiency. Haemophilia. 24:e160–e1e3CrossRefGoogle Scholar
  3. 3.
    Fujita Y, Nakazato T, Ito C, Masuda K, Osada Y, Aisa Y, Mori T (2018) A rare case of an acquired factor V inhibitor in a patient with myelodysplastic syndrome during azacitidine treatment. Ann Hematol 97:2009–2010CrossRefGoogle Scholar
  4. 4.
    Boland F, Shreenivas A (2017) Acquired factor V inhibitors: a review of literature. Ann Hematol Oncol 4:1168CrossRefGoogle Scholar
  5. 5.
    Auffret V, Lefevre T, Van Belle E, Eltchaninoff H, Iung B, Koning R, Motreff P, Leprince P, Verhoye JP, Manigold T, Souteyrand G, Boulmier D, Joly P, Pinaud F, Himbert D, Collet JP, Rioufol G, Ghostine S, Bar O, Dibie A (2017) Temporal trends in transcatheter aortic valve replacement in France: FRANCE 2 to FRANCE TAVI. J Am Coll Cardiol 70:42–55CrossRefGoogle Scholar
  6. 6.
    Franchini M, Castaman G, Coppola A, Santoro C, Zanon E, Di Minno G, Morfini M, Santagostino E, Rocino A (2015) Acquired inhibitors of clotting factors: AICE recommendations for diagnosis and management. Blood Transfus 13:498–513Google Scholar
  7. 7.
    Ang AL, Kuperan P, Ng CH, Ng HJ (2009) Acquired factor V inhibitor. A problem-based systematic review. Thromb Haemost 101:852–859CrossRefGoogle Scholar
  8. 8.
    Koduri PR, Kamineni V, Vedantham H, Joshi N (2016) Laparoscopic surgery in a woman with factor V deficiency: revisiting platelet factor V. Haemophilia. 22:e322–e324CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Laboratoire d’hématologie, Hôpital cardiologiqueCentre Hospitalo-Universitaire de BordeauxPessacFrance
  2. 2.Service de cardiologie interventionnelle, Hôpital cardiologiqueCentre Hospitalo-Universitaire de BordeauxPessacFrance
  3. 3.Unité de de Soins Intensifs et Continus de Cardiologie, Hôpital cardiologiqueCentre Hospitalo-Universitaire de BordeauxPessacFrance
  4. 4.Unité mobile de gériatrie, Hôpital Saint-AndréCentre Hospitalo-Universitaire de BordeauxBordeauxFrance
  5. 5.Service de médecine interne et immunologie clinique, Hôpital Saint-AndréCentre Hospitalo-Universitaire de BordeauxBordeauxFrance
  6. 6.Centre de Ressources et de Compétences des Maladies Hémorragiques Constitutionnelles, Hôpital PellegrinCentre Hospitalo-Universitaire de BordeauxBordeauxFrance
  7. 7.Centre de Référence des Pathologies Plaquettaires Constitutionnelles, Hôpital cardiologiqueCentre Hospitalo-Universitaire de BordeauxPessacFrance
  8. 8.Laboratoire d’HématologieHôpital CardiologiquePessacFrance

Personalised recommendations